Fact-checked by Grok 2 weeks ago

Fumarase

Fumarase, also known as fumarate hydratase (FH), is an enzyme that catalyzes the reversible hydration of fumarate to L-malate, a critical step in the that facilitates aerobic respiration and cellular energy production through the generation of reducing equivalents like NADH. Encoded by the FH gene on 1q43 in humans, fumarase is a highly conserved protein across eukaryotes, producing two isoforms via alternative transcription initiation that are dually localized to the and the , with roughly equal distribution in both compartments to support metabolic flexibility. This dual targeting arises from two translation products, one with a mitochondrial targeting sequence for import and the other lacking it for cytosolic retention, enabling fumarase to participate in both oxidative metabolism and non-mitochondrial pathways. Structurally, fumarase belongs to class II enzymes and forms a homotetrameric complex with a total molecular weight of approximately 200 , consisting of four identical subunits of about 50 each; it operates without requiring cofactors, relying instead on three catalytic residues from adjacent subunits to form the for stereospecific binding. In the TCA cycle, mitochondrial fumarase ensures the continuity of the pathway by interconverting fumarate and malate, linking , , and to ATP synthesis, while cytosolic fumarase contributes to fumarate , function, and biosynthesis. Beyond metabolism, fumarase plays emerging roles in genomic stability: upon DNA double-strand breaks, it translocates to the nucleus, where its enzymatic production of fumarate locally inhibits histone demethylases like KDM2B and KDM4A, promoting chromatin modifications (e.g., H3K36 ) that facilitate via or . Mutations in the FH gene disrupt these functions, leading to fumarase deficiency—a severe autosomal recessive disorder characterized by , seizures, and early lethality due to impaired brain —and hereditary leiomyomatosis and renal cell cancer (HLRCC), an autosomal dominant where heterozygous loss promotes tumorigenesis through fumarate accumulation, pseudohypoxia via HIF-1α stabilization, and increased genomic instability. As a tumor suppressor, fumarase's cytosolic and nuclear activities underscore its integration of with DNA damage response, highlighting its broader implications in cancer predisposition and cellular homeostasis.

Nomenclature

EC Classification

Fumarase is officially classified under the Enzyme Commission (EC) number 4.2.1.2, identifying it as a lyase enzyme that catalyzes the reversible addition of water to a carbon-carbon double bond. This classification places it within the broader category of lyases (EC 4), specifically the subclass of carbon-oxygen lyases (EC 4.2). The systematic name for this enzyme is (S)-malate hydro-lyase (fumarate-forming), reflecting its role in the stereospecific dehydration of (S)-malate to fumarate. Additionally, it is assigned the Chemical Abstracts Service (CAS) registry number 9032-88-6. Within the lyase class, fumarase belongs to the hydro-lyase family (EC 4.2.1), which encompasses enzymes that facilitate the or of unsaturated substrates via elimination or of across double bonds, without involving or phosphorolysis. This distinguishes hydro-lyases like fumarase from other hydratases, such as those in the isomerase class ( 5) or synthases that may employ metal-dependent mechanisms for similar but non-lyase transformations.

Synonyms

Fumarase is commonly referred to by several alternative names in scientific literature, reflecting its enzymatic function and historical context. The most widely used synonym is fumarate hydratase, which emphasizes its role in the hydration of fumarate, while an older term, fumaric acid hydrase, was occasionally employed in early biochemical descriptions. The primary abbreviation for the enzyme is FH, approved by the Human Genome Nomenclature Committee for the corresponding gene; however, this acronym requires contextual distinction in biology, as it also denotes unrelated entities such as factor H (a regulator in the complement system) and familial hypercholesterolemia (a lipid disorder). The nomenclature of fumarase evolved during the elucidation of the tricarboxylic acid cycle in the early , with the term "fumarase" first documented in biochemical publications in 1931 by J. H. Quastel, predating the full description of the cycle by Hans Adolf Krebs in 1937.

Structure

Gene

The human FH gene, which encodes the enzyme fumarate hydratase, is located on the long arm of at cytogenetic band 1q43, spanning genomic coordinates 241497603–241519755 (GRCh38.p14 assembly). This positioning places it within a region associated with various genetic studies, though specific neighboring genes include those involved in metabolic processes. The FH gene structure comprises 10 exons distributed over approximately 22 kb of genomic DNA, with introns separating the coding regions to facilitate proper mRNA processing. The promoter region upstream of the first exon contains a CpG island and multiple transcription start sites, enabling a broad transcriptional initiation pattern that supports ubiquitous expression across tissues such as heart, liver, and kidney. Transcription produces a primary pre-mRNA that undergoes canonical splicing by the spliceosome to yield a mature mRNA of about 1.4 kb, which is then translated into the fumarase protein; alternative transcription initiation, resulting in mRNAs that utilize different translation start sites, contributes to the generation of isoforms. Orthologs of the human FH gene are well-conserved across species, reflecting its essential role in metabolism. In the bacterium Escherichia coli, fumarase activity is encoded by three genes: fumA and fumB (class I fumarases, which are iron-sulfur cluster-containing enzymes) and fumC (a class II fumarase lacking such clusters, serving as a stress-resistant backup). In the yeast Saccharomyces cerevisiae, the single ortholog FUM1 encodes a mitochondrial fumarase that shares structural and functional homology with the human protein. These orthologs have been instrumental in elucidating conserved mechanisms of fumarase function through genetic and biochemical studies in model organisms.

Protein

The human fumarase protein, encoded by the FH gene, comprises 510 residues and has a molecular weight of approximately 50 per subunit. Its secondary structure is predominantly α-helical, featuring a large number of α-helices with limited β-sheet elements integrated into the core domains. Specifically, the central domain (D2) consists of a five-helix bundle, while the peripheral domains (D1 and D3) incorporate mixed α-helices and β-sheets to form the overall scaffold. In terms of tertiary structure, each folds into a compact three-domain : D1 (residues 49–188) with β-α-β motifs, D2 (residues 189–439) as an all-α-helical bundle that mediates intersubunit contacts, and D3 (residues 440–510) featuring additional α-β elements. This arrangement creates a monomeric unit with a crevice-like pocket at the domain interfaces, involving conserved residues such as (e.g., His180), aspartate, and that coordinate binding. High-resolution crystal structures have elucidated these features, including the tetrameric at 1.95 Å resolution (PDB ID: 3E04), which reveals the orthogonal arrangement of domains and the multi-subunit architecture. More recent structures, such as PDB ID: 7LUB (2021), have further elucidated interactions with inhibitors. Complementary models from Escherichia coli fumarase C (e.g., PDB ID: 1FUO) highlight conserved folding patterns across class II fumarases, with the human variant showing 54% sequence identity to the bacterial homolog. The protein typically assembles into a homotetramer, with each subunit contributing to four independent s formed at the interfaces of three monomers.

Isoforms

Fumarase enzymes are classified into two distinct classes based on their structural and biochemical properties. Class I fumarases, primarily found in prokaryotes, are Fe²⁺-dependent enzymes that contain a [4Fe-4S] in their and form homodimers with a molecular weight of approximately 120 kDa. These enzymes are often oxygen-sensitive and exhibit high specificity for the reversible hydration of fumarate to L-malate. In contrast, Class II fumarases, which are predominant in eukaryotes and also present in some prokaryotes, are Mn²⁺-independent (though sometimes activated by Mn²⁺), lack metal cofactors, and assemble into homotetramers with a molecular weight of about 200 kDa. They are characterized by greater thermal stability and broader phylogenetic distribution compared to Class I. In eukaryotes, fumarase isoforms arise from a single gene through dual targeting mechanisms rather than alternative splicing, resulting in proteins localized to both the mitochondrial matrix and the cytosol (with some translocation to the nucleus under stress conditions). The mitochondrial isoform features an N-terminal targeting signal peptide that is cleaved upon import, yielding a mature protein identical in sequence to the cytosolic form at the N-terminus. This dual localization is conserved from yeast to humans, where the fumarate hydratase (FH) gene produces a single translation product that partitions post-translationally between compartments. The cytosolic/nuclear form supports non-canonical roles, such as involvement in DNA damage response. Class II fumarases, including eukaryotic isoforms, form tetramers through specific subunit interfaces that stabilize the oligomeric structure essential for activity. Each subunit consists of three domains—an N-terminal domain, a central five-helix bundle, and a C-terminal domain—with dimer interfaces primarily involving the central and C-terminal regions to create the functional tetrameric core. These interfaces, such as those between subunits A-D and C-D in the tetramer, contribute to the enzyme's overall stability and substrate binding. Species-specific variations in eukaryotic fumarase include differences in targeting and post-translational modifications. The core tetrameric assembly remains conserved across .

Function

Reaction Catalyzed

Fumarase, also known as fumarate hydratase, catalyzes the reversible hydration of fumarate to L-malate, a critical step in cellular . The reaction can be represented as: \text{fumarate} + \text{H}_2\text{O} \rightleftharpoons (S)\text{-malate} This transformation involves the addition of a molecule across the of fumarate, yielding the (S)- of malate with high . The of the reaction features a addition of the hydroxyl group and from to the of fumarate, ensuring the exclusive production of (S)-malate without forming the (R)-. This -specific mechanism is conserved across eukaryotic and prokaryotic fumarases, highlighting its evolutionary importance for precise chiral control in metabolic pathways. In vivo, the reaction predominantly proceeds in the direction of malate formation, particularly within the tricarboxylic acid (TCA) cycle under aerobic conditions, driven by the subsequent oxidation of malate to oxaloacetate. The equilibrium constant (K_eq) for the hydration reaction is approximately 4, favoring malate over fumarate by a ratio of about 4:1 at physiological pH and ionic strength. This bias ensures efficient flux through the TCA cycle despite the reversibility of the enzyme. Class II fumarases, which include the eukaryotic and most prokaryotic forms, operate independently of metal cofactors or prosthetic groups, relying solely on the protein's residues for . This cofactor-free nature distinguishes them from class I fumarases, which require iron-sulfur clusters, and underscores their thermal stability and broad distribution in organisms.

Mechanism

Fumarase catalyzes the reversible hydration of fumarate to L-malate through a base-catalyzed mechanism involving a carbanion intermediate. In the forward (hydration) direction, a water molecule bound in the active site is deprotonated by a histidine residue acting as a general base, generating a nucleophilic hydroxide ion. This hydroxide attacks the electrophilic C2 carbon of fumarate, leading to the addition across the trans double bond and formation of a carbanion at C3. The carbanion is subsequently protonated at C3 to yield L-malate, ensuring stereospecific anti addition. Key residues from multiple subunits of the tetrameric coordinate this process. In fumarase, His235 serves as the general base for deprotonating the or, in the reverse dehydration direction, abstracting the pro-R proton from C3 of malate to initiate formation. Asp232 and Lys324 contribute to stabilizing the intermediate through electrostatic interactions and hydrogen bonding within an extensive network that polarizes the and lowers the barrier. Additional residues, such as Ser186 and Thr234, position the and facilitate proton transfer. The also features a secondary B-site, distinct from the catalytic A-site, which binds fumarate or malate without participating in bond breaking or formation. This allosteric site enhances by accelerating substrate delivery to the and product release, thereby increasing overall reaction efficiency through conformational adjustments that promote rapid turnover.

Kinetic Properties

Fumarase follows Michaelis-Menten kinetics, with reported Km values of approximately 5 μM for fumarate and 25 μM for L-malate in mammalian enzymes such as pig heart fumarase. These low Km values indicate high substrate affinity, enabling efficient catalysis under physiological conditions where substrate concentrations are typically in the micromolar range. The maximum velocity (Vmax) and (kcat) for mammalian fumarase such as pig heart are approximately 800 s⁻¹, reflecting its high catalytic in the . This kcat value positions fumarase among the more efficient s, with a catalytic proficiency (kcat/) approaching the limit for fumarate hydration. The exhibits an optimal of 7.5–8.0, aligning with the slightly alkaline environment of mitochondria, and shows stability across a broad pH range (6.0–9.0). Class II fumarases, including the eukaryotic form, demonstrate thermal stability up to 70°C, though human variants have a lower around 51°C that can be enhanced by ligands. Succinate and phosphate act as competitive inhibitors, binding at the and increasing the apparent for substrates without affecting Vmax. This inhibition mode underscores the enzyme's specificity for trans-aconitate-like substrates in the .

Metabolic Roles

Citric Acid Cycle

Fumarase occupies the seventh position in the tricarboxylic acid () , catalyzing the reversible of fumarate to L-malate following the oxidation of succinate by . This step integrates fumarate, produced upstream in the , into malate, which subsequently serves as a substrate for to generate oxaloacetate and NADH for electron transport. The reaction maintains the cyclic flow of carbon intermediates essential for complete oxidation of derived from carbohydrates, fats, and proteins. In addition to its catabolic role, fumarase contributes to anaplerosis by facilitating the entry of fumarate generated from into the , thereby replenishing depleted intermediates. Specifically, the degradation of and via fumarylacetoacetate yields fumarate, which fumarase then converts to malate to sustain flux during biosynthetic demands or high metabolic turnover. This anaplerotic function ensures the TCA 's capacity to support both energy production and the provision of precursors for and . The mitochondrial localization of fumarase is crucial for coupling cycle activity to , as the enzyme resides in where it coordinates with the to maximize ATP yield. Disruption of this localization impairs the cycle's efficiency, leading to reduced NADH and FADH₂ production and consequently diminished proton gradient formation across the inner membrane. This compartmentalization underscores fumarase's role in aerobic respiration, linking substrate-level metabolism to the proton-motive force driving . Fumarase operates as a near-equilibrium in the TCA cycle, exhibiting rapid forward and reverse kinetics that minimize its contribution to control and prevent it from becoming rate-limiting under physiological conditions. The reaction's favors malate formation but allows bidirectional , enabling quick adjustments to metabolite concentrations without imposing bottlenecks on overall cycle throughput. This property contrasts with irreversible steps earlier in the cycle, ensuring efficient propagation of from upstream dehydrogenases to downstream energy-harvesting processes.

Other Pathways

Fumarase plays a key role in linking the to other metabolic processes by hydrating the fumarate byproduct generated from argininosuccinate cleavage. In the , argininosuccinate lyase catalyzes the breakdown of argininosuccinate into and fumarate, providing fumarate that fumarase subsequently converts to malate for further utilization in cellular metabolism.00645-6) Fumarate produced through serves as a supplier for synthesis pathways, where fumarase facilitates its conversion to support aspartate production essential for . During purine salvage, AMP deaminase generates fumarate as a side product, which fumarase hydrates to malate; this malate is then oxidized to oxaloacetate and transaminated to aspartate, a critical precursor for pyrimidine ring formation in UMP synthesis.51814-0/fulltext) In the , fumarase contributes to by locally generating fumarate that modulates demethylase activity. Upon DNA double-strand breaks, cytosolic fumarase accumulates at damage sites to produce fumarate, which competitively inhibits the α-ketoglutarate-dependent demethylase KDM2B, thereby increasing H3K36me2 marks and promoting repair. Fumarase also protects the mitochondrial cysteine desulfurase Nfs1 from inactivation, linking its activity to DNA damage response pathways, as demonstrated in 2021 yeast studies. In fumarase-deficient cells, Nfs1 undergoes modification and loses function, impairing iron-sulfur cluster biogenesis and ; however, Nfs1 overexpression restores repair efficiency, indicating fumarase's role in maintaining Nfs1 stability.

Regulation

Transcriptional Control

The FH gene, encoding fumarate hydratase, exhibits ubiquitous mRNA expression across human tissues, with notably higher levels observed in the liver, heart, skeletal muscle, and kidney, as well as moderate expression in the brain. This tissue-specific pattern supports the enzyme's role in central metabolic processes, particularly in organs with high energy demands. The promoter region of the FH gene is characterized by a broad structure that facilitates alternative transcription initiation sites, allowing for the production of multiple mRNA isoforms that direct the protein to both mitochondrial and cytosolic compartments. In contexts of metabolic stress, such as in nasopharyngeal carcinoma, the chromatin remodeling factor LSH binds directly to the FH promoter and represses gene expression by recruiting the histone methyltransferase G9a, leading to chromatin modifications that suppress transcription independently of DNA methylation. Regulatory motifs associated with the FH gene demonstrate evolutionary conservation across eukaryotes, mirroring the high sequence and functional preservation of the enzyme itself from yeast to mammals, which underscores the fundamental importance of fumarase in cellular .

Post-Translational Modifications

Fumarase undergoes post-translational processing during its into mitochondria, where the N-terminal presequence of the mitochondrial isoform is cleaved by the mitochondrial processing peptidase (). This cleavage occurs after the precursor protein is translocated across the , generating the mature enzyme and enabling its tetrameric assembly within the matrix. The process ensures proper localization and activation, with studies showing that external can access and cleave the presequence even during ongoing , highlighting the dynamic nature of this modification. Phosphorylation represents a key regulatory modification of fumarase, particularly at serine and residues, which modulates its enzymatic activity in response to metabolic stress. For instance, under glucose deprivation, (AMPK) phosphorylates human fumarase at Ser75, promoting its interaction with activating transcription factor 2 (ATF2) and facilitating a transcriptional response that enhances survival through changes. This event is mutually exclusive with O-GlcNAcylation at the same site by O-GlcNAc transferase (OGT), which predominates in nutrient-rich conditions and suppresses the AMPK-mediated pathway, as observed in cells where high OGT correlates with poor prognosis. Additional phosphorylation sites, such as Thr126, inhibit fumarase activity under basal conditions but are dephosphorylated during DNA damage, thereby increasing enzymatic output to support repair processes. Fumarase is also phosphorylated by the DNA-dependent protein kinase (DNA-PK) complex, which promotes its recruitment to DNA double-strand breaks. Covalent modifications like succinylation and further fine-tune fumarase function, especially in the context of DNA damage response. Succinylation on residues inhibits fumarase activity and impairs its role in both and , but these marks are dynamically removed upon genotoxic stress, leading to a threefold increase in enzymatic activity. suppresses activity, and its reversal during DNA damage enhances fumarase's contribution to metabolic adaptation for repair. In , fumarase deficiency leads to accumulation of inactivating post-translational modifications on the desulfurase Nfs1p, such as deamidation at N128 and Q328 and oxidation at M244, which reduce iron-sulfur cluster biogenesis essential for enzymes; fumarase protects Nfs1p by direct binding and maintaining a reducing , thereby linking its unmodified state to efficient damage response. Acetylation of fumarase is regulated by histone deacetylase 6 (HDAC6), which interacts directly with the enzyme in mitochondrial networks to maintain its activity. Inhibition of HDAC6 with selective inhibitors like BAS-2 reduces fumarase activity, causing fumarate accumulation, increased protein succination, and elevated mitochondrial , ultimately disrupting mitochondrial structure and inducing in cells. This interaction, visualized via , positions HDAC6 as a modulator of fumarase's post-translational state, with deacetylation promoting optimal function in tumor .

Clinical Significance

Deficiency and Metabolic Disorders

Fumarase deficiency, also known as fumarate hydratase (FH) deficiency or fumaric aciduria, is a rare autosomal recessive metabolic disorder, although there is an unusually high incidence among members of the Fundamentalist Church of Jesus Christ of Latter Day Saints in the southwestern United States due to a founder effect, caused by biallelic pathogenic variants in the FH gene, leading to impaired activity of the fumarase enzyme in both mitochondrial and cytosolic compartments. This results in disruption of the citric acid cycle, particularly affecting energy production in high-demand tissues like the brain. Clinical manifestations typically emerge in the neonatal or early infantile period, presenting as severe progressive encephalopathy characterized by poor feeding, hypotonia, lethargy, and failure to thrive. Common neurological symptoms include intractable seizures in approximately 43% of cases, profound developmental delay, and structural brain abnormalities such as ventriculomegaly, polymicrogyria, and agenesis of the corpus callosum. Prenatal indicators often involve polyhydramnios in about 23% of affected pregnancies, alongside fetal brain malformations detectable by ultrasound. Biochemically, the disorder is marked by massive urinary excretion of (fumarate), often accompanied by elevations in other intermediates such as alpha-ketoglutarate and succinyladenosine, reflecting the enzymatic block at the conversion of fumarate to malate. These metabolites may also appear elevated in (CSF), contributing to the observed neurological deterioration, though and pyruvate elevation can occur variably. Systemic features may include neonatal , hepatosplenomegaly, and dysmorphic facial traits like prominent forehead, , and micrognathia, underscoring the multisystem impact. Diagnosis is confirmed through a combination of biochemical and , beginning with analysis of urine organic acids to detect the characteristic fumaric aciduria. Enzymatic assays in fibroblasts, leukocytes, or muscle tissue demonstrate severely reduced FH activity, often below 10-20% of normal levels. Molecular confirmation involves sequencing the FH gene to identify homozygous or compound heterozygous variants, which are essential for carrier screening in families. There is no curative treatment for fumarase deficiency; management remains supportive and multidisciplinary, focusing on symptom control and nutritional support. Seizures are managed with antiepileptic drugs such as or , while feeding difficulties may necessitate tube placement and to address . Emerging evidence from case reports suggests potential benefits from a high-fat, , which in one long-term reduced urinary fumarate levels and mitigated metabolic without adverse effects, contrasting earlier contraindications for ketogenic approaches. Citrate supplementation has been explored in some protocols to bolster flux, though its efficacy remains unproven in large cohorts. The prognosis is generally poor, with most individuals succumbing in early childhood due to progressive and complications like ; however, rare cases with milder phenotypes and supportive interventions may survive into with moderate .

Role in Cancer and Other Diseases

Fumarase (FH), encoded by the FH gene, acts as a tumor suppressor, and its mutations are the primary cause of hereditary leiomyomatosis and renal cell cancer (HLRCC), an autosomal dominant disorder characterized by cutaneous and uterine leiomyomas as well as aggressive papillary type 2 . In HLRCC, FH inactivation leads to accumulation of fumarate, which induces a pseudohypoxic state by stabilizing hypoxia-inducible factor (HIF) through inhibition of prolyl hydroxylases, thereby promoting tumorigenesis via enhanced glycolytic flux and angiogenic signaling. This fumarate-mediated HIF stabilization mimics hypoxic conditions in normoxic environments, driving oncogenesis in renal and other tissues affected by HLRCC. As an oncometabolite, fumarate exerts protumorigenic effects by competitively inhibiting α-ketoglutarate (α-KG)-dependent dioxygenases, including histone and DNA demethylases as well as TET enzymes, leading to epigenetic alterations that favor cancer progression. These inhibitions disrupt normal cellular differentiation, promote genomic instability, and enhance inflammatory signaling, all of which contribute to the oncogenic phenotype in FH-deficient tumors. In various cancer models, fumarate's role as an oncometabolite has been linked to widespread hypermethylation and impaired DNA repair, underscoring FH loss as a driver of metabolic reprogramming in malignancy. In , FH functions as a tumor suppressor by negatively regulating () signaling, thereby inhibiting and . Studies in cell lines demonstrate that FH overexpression suppresses activation and downstream pathways, reducing tumor growth, while FH knockdown enhances invasive potential. This mechanism highlights FH's role in preventing endometrial tumorigenesis through modulation of growth factor signaling. Beyond oncology, anti-fumarase antibodies serve as a serum biomarker predicting favorable responses to anti-vascular endothelial growth factor (anti-VEGF) therapy in patients with diabetic macular edema (DME), with higher baseline titers correlating with improved visual acuity gains. Additionally, inhibition of histone deacetylase 6 (HDAC6) alters FH activity and mitochondrial structure in cancer cells, potentially offering a therapeutic avenue by disrupting FH-dependent metabolic adaptations in tumors. Therapeutic strategies targeting FH restoration, such as gene overexpression in preclinical models, have shown promise in reversing tumorigenic effects; for instance, re-expression of wild-type FH in HLRCC-derived renal cancer cells reduces fumarate levels, normalizes HIF signaling, and impairs tumor growth. In models, FH restoration via suppresses EGFR-driven proliferation, suggesting potential for approaches in FH-deficient malignancies. These findings support exploring FH reconstitution as a targeted intervention to mitigate oncometabolite-driven cancers. Additionally, a phase II trial presented in 2025 demonstrated promising efficacy and safety of first-line plus in patients with advanced fumarate hydratase-deficient .

References

  1. [1]
    FH gene: MedlinePlus Genetics
    Sep 1, 2017 · Specifically, fumarase helps convert a molecule called fumarate to a molecule called malate. Health Conditions Related to Genetic Changes.
  2. [2]
    Fumarase: A Mitochondrial Metabolic Enzyme and a Cytosolic ...
    Mar 9, 2010 · In mitochondria of all cell types, fumarase functions as an enzyme of the TCA cycle. In this regard, human fumarase expressed in yeast ...
  3. [3]
    Fumarase - an overview | ScienceDirect Topics
    Fumarase (Fumarate Hydratase) is an enzyme that catalyzes the reversible dehydration of l-malate to fumaric acid, and is involved in the TCA cycle.
  4. [4]
    Fumarase: From the TCA Cycle to DNA Damage Response and ...
    Fumarase is an enzyme of the tricarboxylic acid (TCA) cycle in mitochondria, but in recent years, it has emerged as a participant in the response to DNA double ...<|control11|><|separator|>
  5. [5]
    EC 4.2.1.2 - IUBMB Nomenclature
    Other name(s): fumarase; L-malate hydro-lyase; (S)-malate hydro-lyase. Systematic name: (S)-malate hydro-lyase (fumarate-forming). Links to other databases ...Missing: family | Show results with:family
  6. [6]
    KEGG ENZYME: 4.2.1.2 - (www.genome.jp).
    EC 4.2.1.2 Enzyme. Name. fumarate hydratase; fumarase; L-malate hydro-lyase; (S)-malate hydro-lyase. Class. Lyases; Carbon-oxygen lyases; Hydro-lyases. BRITE ...Missing: systematic CAS
  7. [7]
    M-CSA Mechanism and Catalytic Site Atlas - EMBL-EBI
    Fumarase C is a member of the class II enzymes, a family which also includes aspartase, adenylosuccinate lyase and arginosuccinate, with high sequence ...
  8. [8]
    Fumarate hydratase, mitochondrial - P07954 - UniProt
    Catalyzes the dehydration of L-malate to fumarate (By similarity). Fumarate metabolism in the cytosol plays a role during urea cycle and arginine metabolism; ...
  9. [9]
    biology medical acronym abbreviation - Chang Bioscience
    FH: fumarate hydratase. FH: formin homology. FH: Familial hypercholesterolemia. FH: factor H FH: familial hypercholesterolaemia. FH: FRAG1 homology. FH ...
  10. [10]
    FUMARASE Definition & Meaning - Merriam-Webster
    aldolase · alleyways · amylase · anaphase · anhydrase · anyways · arginase · cabarets ...<|control11|><|separator|>
  11. [11]
    Fumarate hydratase in cancer research: scientific trends and ... - NIH
    May 29, 2025 · Fumarate hydratase (FH) is a key enzyme in the Krebs cycle and cellular energy metabolism, playing a crucial role in tumorigenesis.
  12. [12]
    2271 - Gene ResultFH fumarate hydratase [ (human)] - NCBI
    Aug 19, 2025 · Novel mutations within the FH gene are associated with hereditary leiomyomatosis and renal cell cancer.
  13. [13]
    Human Fumarate Hydratase Is Dual Localized by an Alternative ...
    Apr 1, 2016 · The FH gene has 10 exons represented by solid black rectangles. ... The existence of a CpG island in the promoter of the FH gene, is ...Results · The Fh Gene Has More Than... · Detection Of The Fh Protein...
  14. [14]
    Fumarase a from Escherichia coli: purification and ... - PubMed
    Oct 27, 1992 · It has been shown previously that Escherichia coli contains three fumarase genes designated fumA, fumB, and fumC.Missing: orthologs yeast
  15. [15]
    Amino acid sequence of porcine heart fumarase - PubMed
    Prediction of the secondary structural elements of porcine fumarase ... a large amount of alpha helix with very little beta structure. Publication ...Missing: sheets | Show results with:sheets
  16. [16]
    Structural basis of fumarate hydratase deficiency - PMC
    Mar 29, 2011 · Fumarate hydratase catalyzes the stereospecific hydration across the olefinic double bond in fumarate leading to L-malate. The enzyme is ...Materials And Methods · Results And Discussion · Table 2
  17. [17]
    Biochemical Characterization of Two Clinically-Relevant Human ...
    Jan 29, 2018 · Fumarase assembles into a homotetramer, with four active sites. Interestingly, residues from three of the four subunits within the homotetramer ...
  18. [18]
    Closed fumarase C active‐site structures reveal SS Loop residue ...
    Sep 12, 2019 · Structural organization of fumarase C (FumC). FumC monomer folds into a three-domain structure. Domain 1 (D1) contains residues 1–140, domain 2 ...Closed Fumarase C... · Results · DiscussionMissing: tertiary | Show results with:tertiary
  19. [19]
    RCSB PDB - 3E04: Crystal structure of human fumarate hydratase
    ### Summary of Structural Features of Human Fumarate Hydratase (PDB ID: 3E04)
  20. [20]
    Structural, biochemical and biophysical characterization of ...
    Feb 14, 2019 · Fumarate hydratases (FHs, fumarases) catalyze the reversible conversion of fumarate into l-malate. FHs are distributed over all organisms ...<|control11|><|separator|>
  21. [21]
    Interchangeability of class I and II fumarases in an obligate ...
    Oct 26, 2023 · These enzymes are oxygen tolerant and strongly specific to fumarate/malate. Class II fumarases can be found in many pro- and eukaryotic ...
  22. [22]
    Revisiting the burden borne by fumarase: enzymatic hydration of an ...
    Sep 3, 2022 · Two classes of FH are observed in nature: class-I and class-II, that have different folds, yet catalyze the same reversible hydration/ ...
  23. [23]
    Mitochondrial and cytosolic isoforms of yeast fumarase ... - PubMed
    Dec 7, 2001 · Mitochondrial and cytosolic isoforms of yeast fumarase are derivatives of a single translation product and have identical amino termini. J ...Missing: eukaryotic | Show results with:eukaryotic
  24. [24]
    The multisubunit active site of fumarase C from Escherichia coli
    The central domain, D2, is a unique five-helix bundle. The association of the D2 domains results in a tetramer which has a core of 20 alpha-helices. The other ...Missing: interfaces | Show results with:interfaces
  25. [25]
    The Substrate Specificity of Fumarase
    In order to interpret the observed differences in the stereo- specificity of the addition of water and the rate of hydration of the fumarase substrates, it is ...
  26. [26]
    The selective addition of water - RSC Publishing
    Aug 14, 2014 · For nearly all tested substrates, water addition took place in a trans fashion. The cis product was found for α-fluoromalate, where spontaneous ...
  27. [27]
    fumA - Fumarate hydratase class I, aerobic | UniProtKB - UniProt
    Catalyzes the reversible hydration of fumarate to (S)-malate. Functions as an aerobic enzyme in the direction of malate formation as part of the citric acid ...
  28. [28]
    The role of the allosteric B site in the fumarase reaction - PNAS
    The malate, within 12 Å of the active site, was bound by hydrogen bonds to two main-chain amides and to two basic residues, H129 and R126. Mutation of the His ...Abstract · Sign Up For Pnas Alerts · Results And DiscussionMissing: human | Show results with:human
  29. [29]
    Fumarase: a paradigm of dual targeting and dual localized functions
    Sep 19, 2011 · In the case of fumarase, the cytoplasmic function was only recently discovered; the enzyme was found to participate in the cellular response to ...
  30. [30]
    Electrostatic Edge: Decrypting the Near-Perfect Catalytic Efficiency of Fumarase
    ### Summary of Carbanionic Pathway for Fumarase Catalysis
  31. [31]
    FEBS Press
    ### Kinetic Parameters for Human Recombinant Fumarate Hydratase (HsFH)
  32. [32]
    Biochemical characterisation of fumarase C from a unicellular ...
    Jul 23, 2019 · SyFumC was thus biochemically characterised, including identification of an amino acid residue important for substrate affinity and enzymatic activity.<|control11|><|separator|>
  33. [33]
    Identification of the Catalytic Mechanism and Estimation of Kinetic ...
    Fumarase catalyzes the reversible hydration/dehydration of fumarate (FUM) to malate (MAL) through the biochemical reaction (i.e. involving biochemical reactants ...
  34. [34]
    Biochemistry, Citric Acid Cycle - StatPearls - NCBI Bookshelf - NIH
    Steps of the Citric Acid Cycle:​​ Fumarase is the catalyst in the hydration of fumarate to malate. [8] This reaction is reversible.
  35. [35]
    Coupling Krebs cycle metabolites to signalling in immunity and cancer
    Apr 26, 2019 · ... tyrosine metabolism and is produced from the urea and purine nucleotide cycles. Fumarate is then broken down to malate by the enzyme fumarate ...Coupling Krebs Cycle... · 3. Itaconate As A Key... · 3.1. Itaconate Is An...<|separator|>
  36. [36]
    CDC5L drives FAH expression to promote metabolic reprogramming ...
    FAH catalyzes the conversion of 4-fumarylacetoacetate to acetoacetate and fumarate from L-phenylalanine and tyrosine catabolism. Through FAH knockdown and ...
  37. [37]
    The emerging role of fumarate as an oncometabolite - PubMed Central
    Jul 31, 2012 · In the mitochondria, FH catalyses the hydration of fumarate to generate malate as part of the Krebs cycle. This pathway is not only essential ...
  38. [38]
    The Pleiotropic Effects of Fumarate: From Mitochondrial Respiration ...
    Jul 24, 2023 · In this context, class-I fumarases participate in the DDR, while class-II fumarase has a role in the OXPHOS. The former plays a role in DDR on ...
  39. [39]
    Fast Isotopic Exchange between Mitochondria and Cytosol in Brain ...
    The absence of fumarase in brain cytosol, the rapid near equilibrium reactions catalyzed by fumarase, malate dehydrogenase and aspartate aminotransferase ...
  40. [40]
    Human argininosuccinate lyase: A structural basis for intragenic ...
    ... residues directly involved in catalysis. Indeed, His-160 is found at the putative ASL active site and corresponds to His-188 in fumarase C, which forms a ...Sign Up For Pnas Alerts · Structure Solution And... · Results And Discussion
  41. [41]
    Metabolic Fate of Fumarate, a Side Product of the Purine Salvage ...
    Fumarate gets converted to malate and then subsequently to aspartate through a metabolic pathway that involves fumarate hydratase, malate quinone oxidoreductase ...
  42. [42]
    Local generation of fumarate promotes DNA repair through ... - NIH
    Mar 21, 2016 · Locally generated fumarate inhibits KDM2B histone demethylase activity, resulting in enhanced dimethylation of histone H3 K36.
  43. [43]
    Fumarase affects the deoxyribonucleic acid damage response by ...
    Nov 19, 2021 · The Krebs TCA cycle enzyme fumarase is a metabolic enzyme that converts fumarate to L-malate in the mitochondria of eukaryotes and in the ...
  44. [44]
    Purification and Characterization of Fumarase from ... - ResearchGate
    Substrate analogs, meso-tartrate, D-tartrate, and pyromellitate, inhibited the enzyme competitively, and D-malate in mixed-type. ResearchGate Logo. Discover ...
  45. [45]
    Tissue expression of FH - Summary - The Human Protein Atlas
    No readable text found in the HTML.<|separator|>
  46. [46]
    Chromatin remodeling factor LSH affects fumarate hydratase as a ...
    Jul 30, 2016 · We found that LSH was associated with the fh promoter; therefore, FH may serve as a direct target of LSH function. However, LSH may repress the ...
  47. [47]
    Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism
    Sep 9, 2023 · Fumarate hydratase (FH) is an enzyme of the Tricarboxylic Acid (TCA) cycle whose mutations lead to hereditary and sporadic forms of cancer.
  48. [48]
    The presequence of fumarase is exposed to the cytosol ... - PubMed
    The presequence of fumarase was cleaved by externally added MPP during import, indicating a lack of, or a loose physical connection between, the translation and ...
  49. [49]
    The decisive role of fumarase: Responsive signaling to glucose ...
    Our recent study shows that AMPK normally phosphorates fumarase (FH) at Ser75 under glucose deprivation, resulting in FH-ATF2 complex formation that ...
  50. [50]
    (PDF) Post-translational Modifications of Fumarase Regulate its ...
    Aug 7, 2025 · This report is the first to demonstrate how post-translational modifications influence the catalytic and DNA repair functions of fumarase in the cell.
  51. [51]
  52. [52]
    Inhibition of HDAC6 alters fumarate hydratase activity and ... - Nature
    Jul 28, 2025 · Fumarate hydratase (FH), a key node of mitochondrial metabolism, is also a tumour suppressor. Despite its prominent roles in tumourigenesis ...Missing: dysfunction | Show results with:dysfunction
  53. [53]
    Fumarate Hydratase Deficiency - GeneReviews® - NCBI Bookshelf
    Jul 5, 2006 · Fumarate hydratase (FH) deficiency results in severe neonatal and early infantile encephalopathy that is characterized by poor feeding, failure to thrive, ...
  54. [54]
  55. [55]
    Fumarase deficiency - Genetics - MedlinePlus
    Sep 1, 2017 · Fumarase deficiency is a condition that primarily affects the nervous system, especially the brain. Affected infants may have an abnormally small head size.
  56. [56]
    Fumarase Deficiency: A Safe and Potentially Disease Modifying ...
    Fumarate hydratase deficiency, also known as fumarase deficiency, is a rare autosomal recessive disorder of the tricarboxylic acid (TCA) cycle. Fumarate ...Missing: citric | Show results with:citric
  57. [57]
    Fumarase Deficiency: Signs, Causes, And Treatment
    Medications such as citrate and malate supplements may be prescribed to help replenish depleted levels of citrate and malate in individuals with fumarase ...
  58. [58]
    Hereditary leiomyomatosis and renal cell cancer (HLRCC ... - PMC
    HLRCC is caused by germline mutations in the fumarate hydratase (FH) gene, which inactivates the enzyme and alters the function of the tricarboxylic acid (TCA/ ...
  59. [59]
    HIF and fumarate hydratase in renal cancer - Nature
    Jan 9, 2007 · Affected individuals harbour a germline mutation of the fumarate hydratase (FH) gene, which encodes an enzyme that catalyses conversion of fumarate to malate ...
  60. [60]
    Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic ...
    Further support for hypoxia-independent HIF activation in HLRCC tumor samples is provided by a recent study of FH knockout mice, in which developing renal cysts ...
  61. [61]
    Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism
    Sep 9, 2023 · Fumarate hydratase (FH) is an enzyme of the Tricarboxylic Acid (TCA) cycle whose mutations lead to hereditary and sporadic forms of cancer.
  62. [62]
    Fumarate hydratase functions as a tumor suppressor in endometrial ...
    Aug 23, 2023 · The present study suggested that FH is a tumor suppressor and inhibits endometrial cancer cell proliferation and metastasis by inactivation of EGFR.
  63. [63]
    Anti-Fumarase Antibody as a Predictor of Functional ... - PubMed
    Feb 1, 2019 · Conclusions: Anti-fumarase antibody is a novel serum biomarker predicting better functional efficacy of anti-VEGF treatment for DME. Publication ...Missing: 2025 | Show results with:2025